Johnson & Johnson

JNJ

NYSE

167.33

USD

+2.59(+1.57%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

Johnson & Johnson fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

17.92

Price/Book

5.16

Debt/Equity

64.69%

Return on Equity

30.39%

Dividend Yield

3.00%

EBITDA

24.78B

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Statements Highlights

AnnualQuarterly

Period Ending	Jan 03, 2021	Jan 02, 2022	Jan 01, 2023	Dec 31, 2023	Dec 29, 2024
Total Revenue	82,584,000,000	78,740,000,000	79,990,000,000	85,159,000,000	88,821,000,000
Gross Profit	54,157,000,000	55,338,000,000	55,394,000,000	58,606,000,000	61,350,000,000
Operating Income	19,733,000,000	20,943,000,000	21,013,000,000	23,409,000,000	22,149,000,000
Net Income	14,714,000,000	20,878,000,000	17,941,000,000	35,153,000,000	14,066,000,000
Total Assets	174,894,000,000	182,018,000,000	187,378,000,000	167,558,000,000	180,104,000,000
Total Current Liabilities	42,493,000,000	45,226,000,000	55,802,000,000	46,282,000,000	50,321,000,000
Total Equity	63,278,000,000	74,023,000,000	76,804,000,000	68,774,000,000	71,490,000,000
Free Cash Flow	20,189,000,000	19,758,000,000	17,185,000,000	18,248,000,000	19,842,000,000
Cash from Operations	23,536,000,000	23,410,000,000	21,194,000,000	22,791,000,000	24,266,000,000
Cash from Investing	-20,825,000,000	-8,683,000,000	-12,371,000,000	878,000,000	-18,599,000,000
Cash from Financing	-6,120,000,000	-14,047,000,000	-8,871,000,000	-15,825,000,000	-3,132,000,000
Net Change in Cash	-3,320,000,000	502,000,000	-360,000,000	7,732,000,000	2,246,000,000

Johnson & Johnson

JNJ

167.33

Johnson & Johnson fundamentals

Key ratios

Statements Highlights

Dividends

Analyst Recomendations